AstraZeneca announced a C$820 million (US$570 million) investment in Canada, creating over 700 high-skilled jobs and supporting a move to a state-of-the-art facility in the Greater Toronto Area. This investment aligns with AstraZeneca's global goals to achieve US$80 billion in revenue and deliver 20 new medicines by 2030, with eight already introduced and seven Phase III clinical trial readouts expected in 2025.

AstraZeneca has been a leading R&D investor in Canada, contributing over C$230 million in 2023, supporting more than 210 global clinical studies. Including this new funding, AstraZeneca's investments in Canada since 2023 exceed C$1.3 billion, creating 1,200 jobs. In 2024, AstraZeneca also completed a C$3 billion acquisition of Fusion Pharmaceuticals in Hamilton, Ontario, further boosting its cancer radiotherapy research.

CEO Pascal Soriot emphasized Canada’s potential as a global hub for life sciences, citing its diverse talent pool and collaboration with Ontario’s government. Premier Doug Ford highlighted the government's support of C$16.1 million via Invest Ontario to attract jobs and innovation to the province.

AstraZeneca's Canadian R&D and rare disease hubs are leading clinical studies in oncology, respiratory, and rare diseases, solidifying the company’s role in advancing global healthcare innovation.